BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 29145648)

  • 1. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
    Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
    J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why does cervical cancer occur in a state-of-the-art screening program?
    Castle PE; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Schiffman M
    Gynecol Oncol; 2017 Sep; 146(3):546-553. PubMed ID: 28606721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women.
    Wentzensen N; Fetterman B; Castle PE; Schiffman M; Wood SN; Stiemerling E; Tokugawa D; Bodelon C; Poitras N; Lorey T; Kinney W
    J Natl Cancer Inst; 2015 Dec; 107(12):djv257. PubMed ID: 26376685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
    Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
    Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
    Silver MI; Schiffman M; Fetterman B; Poitras NE; Gage JC; Wentzensen N; Lorey T; Kinney WK; Castle PE
    Cancer; 2016 Dec; 122(23):3682-3686. PubMed ID: 27657992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting.
    Austin RM; Onisko A; Zhao C
    Am J Clin Pathol; 2018 Oct; 150(5):385-392. PubMed ID: 30137189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States.
    Kaufman HW; Alagia DP; Chen Z; Onisko A; Austin RM
    Am J Clin Pathol; 2020 Sep; 154(4):510-516. PubMed ID: 32637991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.
    Blatt AJ; Kennedy R; Luff RD; Austin RM; Rabin DS
    Cancer Cytopathol; 2015 May; 123(5):282-8. PubMed ID: 25864682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting.
    Landy R; Schiffman M; Sasieni PD; Cheung LC; Katki HA; Rydzak G; Wentzensen N; Poitras NE; Lorey T; Kinney WK; Castle PE
    Int J Cancer; 2020 Feb; 146(3):617-626. PubMed ID: 30861114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
    Befano B; Wentzensen N; Lorey T; Poitras N; Cheung LC; Schiffman M; Clarke MA; Cohen C; Kinney W; Locke A; Castle PE
    Gynecol Oncol; 2024 May; 184():89-95. PubMed ID: 38301311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.
    Li Z; Austin RM; Guo M; Zhao C
    Arch Pathol Lab Med; 2012 Dec; 136(12):1533-40. PubMed ID: 22900617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
    Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
    Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical performance of primary HPV screening, primary HPV screening plus cytology cotesting, and cytology alone at a tertiary care hospital.
    Choi JW; Kim Y; Lee JH; Kim YS
    Cancer Cytopathol; 2016 Feb; 124(2):144-52. PubMed ID: 26457676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
    Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
    Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
    Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
    Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China's largest independent operator of pathology laboratories.
    Xie F; Zhang L; Zhao D; Wu X; Wei M; Zhang X; Wu X; Fang H; Xu X; Yang M; Qi D
    BMC Infect Dis; 2019 Nov; 19(1):962. PubMed ID: 31711435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
    Gage JC; Schiffman M; Katki HA; Castle PE; Fetterman B; Wentzensen N; Poitras NE; Lorey T; Cheung LC; Kinney WK
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25038467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-specific 3-year cumulative risk of cervical cancer and high-grade dysplasia on biopsy in 9434 women who underwent HPV cytology cotesting.
    Ge Y; Christensen PA; Luna E; Armylagos D; Xu J; Hsu JW; Zhou H; Schwartz MR; Mody DR
    Cancer Cytopathol; 2019 Dec; 127(12):757-764. PubMed ID: 31589379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Melnikow J; Henderson JT; Burda BU; Senger CA; Durbin S; Weyrich MS
    JAMA; 2018 Aug; 320(7):687-705. PubMed ID: 30140883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
    Hammer A; Demarco M; Campos N; Befano B; Gravitt PE; Cheung L; Lorey TS; Poitras N; Kinney W; Wentzensen N; Castle PE; Schiffman M
    Int J Cancer; 2020 Sep; 147(6):1612-1620. PubMed ID: 32141607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.